dromlakhani Head/Neck PGL Surveillance vs Intervention Decision
STEP 1 — Gather Information
Collect symptom status (asymptomatic vs symptomatic: headache, pulsatile tinnitus, hearing loss, cranial nerve deficits), tumor growth rate via serial imaging (MRI head/neck with contrast, skull base CT), catecholamine activity (plasma-free fractionated metanephrines, normetanephrines, 3-MT if available), imaging extent (whole-body contrast MRI, skull base contrast CT, 18F-FDG PET/CT, 123I-MIBG scintigraphy), genetic testing for SDHD, family history, and multiplicity of lesions.
STEP 2 — Rule In / Rule Out
Rule out high-risk features: symptomatic presentation, rapid tumor growth (>0.4 mm/year for jugular bulb, >1.6 mm/year for carotid body/vagus nerve), catecholamine production, skull base compression, cranial nerve symptoms, metastasis, or multiple lesions. If any high-risk feature present → proceed to intervention pathway; if none present → proceed to surveillance pathway.
STEP 3 — Classify or Stratify
Stratify into low-risk (asymptomatic, slow-growing, non-functional, solitary lesion) vs high-risk (symptomatic, rapid growth, functional, skull base compression, cranial nerve symptoms, metastasis, or multiple lesions). Low-risk favors surveillance; high-risk favors intervention.
STEP 4 — Decide
For low-risk: initiate surveillance therapy with contrast-enhanced head and neck MRI at 6 months, then annually for 3 years, every other year for up to 6 years, then every 3 years thereafter. For high-risk: pursue surgical resection or gamma knife radiation therapy; for multiple lesions or distant metastases, employ multidisciplinary approach including radionuclide therapy (131I-MIBG, 177Lu-DOTATATE) and chemotherapy (CVD regimen).
Clinical Guardrails / Mimics / Pitfalls
Avoid surgery in asymptomatic, slow-growing HNPGL due to high postoperative complication rates (swallowing problems, airway obstruction 54–60%). Do not rely on fine needle cytology for diagnosis (low accuracy, risk of hypertensive emergency). Ensure genetic testing for SDHD germline variants in all HNPGL cases due to multifocality risk. MIBG scintigraphy has low sensitivity in HNPGL; negative scan does not rule out lesion.
Concrete Clinical Example
A 45-year-old woman presents with a newly diagnosed left carotid body tumor, asymptomatic, MRI shows 1.2 cm lesion, stable over 12 months, normal plasma metanephrines, no SDHD mutation identified, solitary lesion. Decision: surveillance with contrast-enhanced MRI in 6 months.
Source: Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, doi:10.1507/endocrj.EJ25-0165